FIGURE 6 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

scRNA-seq highlights neutrophil heterogeneity shifts in response to EZH2 inhibition combined with immunotherapy. A, Annotated UMAP plot showing the 16 different populations within lung tumors of the Lkb1/Pten model of LSCC after treatment with placebo, GSK126, anti-PD1, or combined GSK126 with anti-PD1. B, Percentage of cells per treatment group graphed for all populations, # indicates adjusted P C, GSEA depicting gene sets that are enriched or depleted in Tumor, Macrophage/Dendritic Cells, or Neutrophils in mice treated with EZH2 inhibitor and anti-PD1 contrasted with either treatment alone. Normalized enrichment scores are plotted and bubble sizes estimate FDR. See also Supplementary Table S2. D, Heat maps showing DEGs among tumor, macrophages, and dendritic cells, and neutrophils between GSK126, anti-PD1, and combination treated mice compared with placebo. E, UMAP of five neutrophil populations showing selected genes that are highly expressed in each cluster. See also Supplementary Fig. S6.